• Disease-a-month : DM · Sep 2020

    Review

    COVID-19: Therapeutics and interventions currently under consideration.

    • R B McFee.
    • Medical Director, Ellis Medical Consulting, Massachusetts, USA. Electronic address: drmcfee2020@gmail.com.
    • Dis Mon. 2020 Sep 1; 66 (9): 101058.

    AbstractWith the emergence of COVID-19 extensive research began to identify medications, candidate compounds and other therapeutic approaches. The complex virology of COVID-19 may provide multiple potential target points for antiviral therapy, and vaccines; extensive global research is underway to exploit these potential opportunities. The complex pathophysiology, pulmonary and extrapulmonary disease, and immune mediated effects such as cytokine storm, make medical management more challenging than many viral illnesses. Non medication based interventions including hyperbaric oxygen (HBOT), extracorporeal membrane oxygenation (ECMO), aggressive dialysis, and other interventions, all with various degrees of clinical success, and will be discussed in this section. Several antivirals approved for other clinical indications were studied for repurposing against COVID-19, which we highlight, again with varying results. In addition to therapeutics, concern was raised over potential risks associated with ACE inhibitors and ARB use, which is presented. Often the timing of the medication determined its clinical benefit as will be discussed with dexamethasone and other medications. As such, this Therapeutics Review will present prominent and/or promising medications and therapeutic approaches with the caveats that 1. To date, none are FDA approved beyond emergency use authorization (EUA), and 2. Although a comprehensive look at various classes of interventions, it is by no means a complete list of every compound trialed against COVID-19. Recognizing the knowledge basis upon which we treat COVID-19 patients, develop therapeutics, and vaccines continues to evolve as new information is presented, every effort nevertheless has been made to provide as timely information as possible. It is hoped that the information shared can help guide the clinician in terms of potential options to treat this complex group of patients.Copyright © 2020 Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…